Home
/
Avalo Therapeutics, Inc.
/
Financials
/
Quarterly
Avalo Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Avalo Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$4.48M
May 11, 2018
Q3
2017
Sep 30, 2017
$25.04M
Nov 7, 2017
Q1
2018
Mar 31, 2017
$384.2K
May 11, 2018
Q3
2017
Sep 30, 2016
$321.5K
Nov 7, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q3
2025
Sep 30, 2024
$249.0K
Nov 6, 2025
Q2
2024
Jun 30, 2024
$0
Aug 12, 2024
Q1
2024
Mar 31, 2024
$0
Jul 11, 2024
Q3
2024
Sep 30, 2023
$236.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$643.0K
Aug 12, 2024
Q1
2024
Mar 31, 2023
$475.0K
Jul 11, 2024
Q3
2023
Sep 30, 2022
$14.95M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$1.03M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$1.17M
May 4, 2023
Q3
2022
Sep 30, 2021
$1.35M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$3.36M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$473.0K
May 5, 2022
Q3
2021
Sep 30, 2020
$1.11M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$1.34M
Aug 2, 2021
Q1
2021
Mar 31, 2020
$2.75M
May 13, 2021
Q3
2020
Sep 30, 2019
$2.20M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$1.39M
Aug 6, 2020
Q1
2020
Mar 31, 2019
$2.58M
May 7, 2020
Q3
2019
Sep 30, 2018
$4.07M
Nov 14, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.63M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($20.77M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($13.15M)
May 12, 2025
Q3
2025
Sep 30, 2024
$23.04M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$98.46M
Aug 7, 2025
Q1
2025
Mar 31, 2024
($121.29M)
May 12, 2025
Q3
2024
Sep 30, 2023
($5.23M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($8.19M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($9.96M)
Jul 11, 2024
Q3
2023
Sep 30, 2022
$3.19M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($12.99M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($22.05M)
May 4, 2023
Q3
2022
Sep 30, 2021
($17.40M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($17.11M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($30.68M)
May 5, 2022
Q3
2021
Sep 30, 2020
($13.46M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($13.28M)
Aug 2, 2021
Q1
2021
Mar 31, 2020
($21.12M)
May 13, 2021
Q3
2020
Sep 30, 2019
($4.02M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($6.22M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($19.20M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($19.32M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($14.67M)
May 12, 2025
Q3
2025
Sep 30, 2024
($12.86M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($9.58M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($32.77M)
May 12, 2025
Q3
2024
Sep 30, 2023
($3.75M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($7.15M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($8.79M)
Jul 11, 2024
Q3
2023
Sep 30, 2022
$4.10M
Nov 9, 2023
Q2
2023
Jun 30, 2022
($11.83M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($20.85M)
May 4, 2023
Q3
2022
Sep 30, 2021
($16.46M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($17.13M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($30.58M)
May 5, 2022
Q3
2021
Sep 30, 2020
($13.28M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($11.82M)
Aug 2, 2021
Q1
2021
Mar 31, 2020
($31.41M)
May 13, 2021
Q3
2020
Sep 30, 2019
($2.86M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($2.55M)
Aug 6, 2020